• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of neurorxLink to Publisher's site
NeuroRx. Oct 2005; 2(4): 662–670.
PMCID: PMC1201323

Targeting Chronic and Neuropathic Pain: The N-type Calcium Channel Comes of Age


Summary: The rapid entry of calcium into cells through activation of voltage-gated calcium channels directly affects membrane potential and contributes to electrical excitability, repetitive firing patterns, excitation-contraction coupling, and gene expression. At presynaptic nerve terminals, calcium entry is the initial trigger mediating the release of neurotransmitters via the calcium-dependent fusion of synaptic vesicles and involves interactions with the soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex of synaptic release proteins. Physiological factors or drugs that affect either presynaptic calcium channel activity or the efficacy of calcium-dependent vesicle fusion have dramatic consequences on synaptic transmission, including that mediating pain signaling. The N-type calcium channel exhibits a number of characteristics that make it an attractive target for therapeutic intervention concerning chronic and neuropathic pain conditions. Within the past year, both U.S. and European regulatory agencies have approved the use of the cationic peptide Prialt for the treatment of intractable pain. Prialt is the first N-type calcium channel blocker approved for clinical use and represents the first new proven mechanism of action for chronic pain intervention in many years. The present review discusses the rationale behind targeting the N-type calcium channel, some of the limitations confronting the widespread clinical application of Prialt, and outlines possible strategies to improve upon Prialt's relatively narrow therapeutic window.

Keywords: N-type calcium channel, Prialt, chronic pain, neuropathic pain, ω-conotoxin


Native calcium channels have been classified by both their electrophysiological and pharmacological properties and are generally divided into low-threshold (T-types) and high threshold (L-, N-, P/Q- and R-types). The L-, N-, P/Q- and R-type channels typically activate at membrane potentials near −30 mV and display diverse kinetic, voltage-dependent and pharmacological properties.1 The availability of specific pharmacological agents targeting the high threshold channels has permitted elucidation of many of their physiological functions. The T-type calcium channels describe a class of molecules that transiently activate at relatively negative potentials (~−60 mV) and for which a general lack of high-affinity selective blockers has made their exact physiological contributions lag behind those of the high-voltage activated isoforms.

High-threshold neuronal calcium channels are heterotrimeric complexes consisting of a pore-forming α1-subunit containing four conserved structural domains (domains I-IV) linked by hydrophilic linkers modeled to be cytoplasmic, a β-subunit that interacts cytoplasmically with the α1-subunit in the domain I-II linker, and an α2δ-subunit that contains a single transmembrane segment covalently linked to an extracellular heavily glycosylated component (Fig. 1A). 2 Although the existence of alternatively spliced variants can complicate attempts to correlate exactly native calcium currents with the biophysical properties of cloned calcium channels, it is generally accepted that the distinct α1-subunits account for all known voltage-gated calcium currents; α1S (Cav1.1), α1C (Cav1.2), α1D (Cav1.3) and α1D (Cav1.4) all encode L-type channels, α1A (Cav2.1) encodes the P/Q-type, α1B (Cav2.2) the N-type, α1E (Cav2.3) the R-type, whereas α1G (Cav3.1), α1H (Cav3.2) and α1I (Cav3.3) all encode low-threshold T-type currents (Fig. 1B). In the mammalian genome, there are also four different β-subunit genes (β1–β4) and four α2δ-subunit genes (α2δ-1–α2δ-4).1

FIG. 1.
Schematic showing the subunit composition of the N-type calcium channel. A: The channel complex consists of pore-forming α1-subunit that also contains the voltage sensor and is the target of pharmacological agents, a β-subunit that modulates ...

Immunohistochemical studies show that most neurons express multiple types of α1- and β-subunits, although differences in the relative levels of expression of individual subtypes are found throughout the CNS. For example, the α1C and α1D L-types and α1E R-type subunits are primarily localized on cell bodies and proximal dendrites, whereas the α1A P/Q-type and α1B N-type subunits are more highly distributed along the lengths of dendrites and at presynaptic terminals.3 These distinctions are not absolute because α1E R-type channels are also detected in cerebellar Purkinje cell dendritic branches and α1A P/Q-type channels are abundantly expressed on Purkinje cell bodies. That each of the classes of calcium channels shows a distinct expression pattern likely reflects their specialized physiological roles. For example, that α1A (Cav2.1) and α1B (Cav2.2) subunits are concentrated at a large number of presynaptic terminals is consistent with a prominent role for N-type and P/Q-type channels in triggering neurotransmitter release.4 That the α1C (Cav1.2) and α1D (Cav1.3) L-type channels appear to be largely restricted to cell bodies and proximal dendrites suggests that they likely serve to increase calcium influx at the base of major dendrites in response to the summation of synaptic inputs from dendritic trees and to also regulate somatic calcium-dependent signaling pathways (e.g., gene regulation).

In addition to their normal physiological functions, calcium channels are also implicated in a number of human pathophysiological conditions including congenital migraine, cerebellar ataxia, neuropathic/chronic pain, angina, epilepsy, hypertension, ischemia, and some arrhythmias. The clinical treatment of some of these disorders has been aided by the development of therapeutic calcium channel antagonists that selectively target those L-type channels largely localized to smooth muscle and the heart.5


Biochemical purification of native N-type channels using cone snail peptide toxins as affinity ligands show the channel is a hetero-oligomeric complex consisting of α1B- (Cav2.2), β-, and α2δ-subunits.2 There is no firm evidence that the N-type channel complex contains a γ-subunit similar to that found in the skeletal muscle L-type channel complex. The large α1B-subunit (~2300 amino acid; ~260 kDa) contains the channel pore, selectivity filter, and voltage-sensing machinery and is the target of all known pharmacological agents. Exogenous expression studies show that the voltage-dependent and kinetic properties of the α1B N-type channel can be differentially affected by co-expression with the distinct β-subunit isoforms.6 The β-subunits also play a key role in N-type channel modulation via both G protein- and protein kinase C-dependent mechanisms.7,8

Whereas pharmacologically defined L-type and T-type currents are each encoded by multiple α1-subunit genes (Fig. 1B), the α1B-subunit is encoded by a single gene. The degree of similarity between N-type channels is significantly greater across species (e.g., rat α1B N-type vs human α1B N-type ~91% identity) than within the same species between N-type channels and the next closely related P/Q-type and R-type channels (rat N-type vs rat α1A P/Q-type ~61% identity; rat N-type vs rat α1E R-type ~55% identity). The higher degree of N-type channel similarity between species is consistent with the significant conservation of both biophysical and pharmacological properties between rat, rabbit, and human N-type channels.

RNA analyses show that α1B transcripts are exclusively expressed in neurons and neuroendocrine cells such as chromaffin cells.9,10 In the CNS, α1B N-type channel mRNA is found in the cerebral cortex, hippocampus, forebrain, midbrain, cerebellum, brainstem, and spinal cord. Alternatively spliced variants have been identified that differ in primary sequence in domain IIIS3-S4, IVS3-S4, II-III linker, and the carboxyl tail region. In some instances, these variants alter channel biophysical properties and exhibit cell type-specific expression patterns (e.g., brain vs peripheral neurons), and there is some suggestion that primary afferents may exclusively express a particular N-type variant.11,12 Although there have been no reports that specific alternatively spliced N-type channel variants alters pharmacological properties, splicing variants in homologous extracellular regions of the P/Q-type channel have been shown to affect the binding of certain peptide toxins.13

At the subcellular level, immunostaining shows α1B-subunits to be predominantly but unevenly clustered along dendritic regions and more diffusely and less frequently on cell bodies throughout the CNS.3 These results are largely in agreement with autoradiographic analyses using radiolabeled ω-conotoxin-GVIA, although they suggest a more specific distribution compared with that reported for a monoclonal antibody against ω-conotoxin-GVIA itself.14 In agreement with pharmacological analyses showing that blockade of N-type channels disrupts a portion of central neurotransmission,4 α1B-subunits are found highly concentrated at a limited subset of presynaptic terminals in the central and peripheral nervous systems.3

N-type channel activity can be modulated by activation of a number of G protein-coupled receptors (GPCRs).15 Of particular relevance, N-type currents are inhibited by GPCRs implicated in nociception including opioid,8,16 cannabinoid,17 neuropeptide Y,18 and substance P.19 In the spinal cord, opioids likely produce their antinociceptive actions act via a combination of two major mechanisms, both of which act via G protein-dependent pathways. In the one instance, activation of opioid receptors (both pre- and postsynaptic) releases Gβγ from the trimeric G-αβγ complex and Gβγ then physically interacts with potassium channels to up-regulate channel activity, hyperpolarizing the cell and decreasing synaptic excitability. In the second instance, the same opioid receptor G protein-dependent pathway results in Gβγ molecules directly binding to presynaptic N-type calcium channels (in 1:1 stoichiometry) stabilizing the closed state and resulting in a ten-fold increase in the first latency of channel opening.2022 A direct consequence of decreasing presynaptic N-type channel activity is likely to significantly attenuate neurotransmitter release in response to subsequent incoming action potentials.

Evidence suggests that the opioid receptor-mediated regulation of N-type currents by Gβγ is, however, significantly more complicated. For example, the inhibition by Gβγ is strongly voltage dependent, can be relieved by rapid trains of action potentials, is affected by the nature of the calcium channel β-subunit associated with the N-type channel complex (e.g., β1 vs β2a), and the Gβγ interaction can be itself inhibited by the PKC-dependent phosphorylation of the N-type channel.8,20 Additionally, presynaptic N-type channels are also physically associated with the neurotransmitter release machinery, most specifically with the soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptor (SNARE) proteins, syntaxin-1A and SNAP-25, through a binding site in the N-type α1B-subunit domain II-II linker.23 Disruption of this α1B-subunit-synaptic protein interaction inhibits neurotransmitter release in cultured neurons. In the absence of exogenous G protein activation, syntaxin-1A can cause tonic inhibition of N-type channel activity, and syntaxin-1A itself also binds Gβγ.24,25 Finally, a class of molecules called regulator of G protein signaling proteins can both alter the kinetics of Gβγ-mediated responses and also interfere with Gβ actions on effectors including N-type calcium channels. The overlapping nature and complexity of these modulatory pathways, combined with the fact that multiple types of GPCRs are implicated in both nociception and N-type channel regulation, makes it difficult to make definitive conclusions concerning their individual roles in any particular nociceptive behavior.


To a large degree, the case for involvement of N-type channels in various pathophysiological conditions rests with studies using high-affinity, selective peptides targeting N-type channels, as well as more recent work examining mice in which the N-type channel has been genetically deleted.

Two cone snail peptides, ω-conotoxin-GVIA and ω-conotoxin-MVIIA (also called SNX-111, Ziconotide and Prialt), have been the workhorses of numerous biochemical, pharmacological, and physiological studies examining the properties and roles of N-type channels.26,27 The 27-amino acid ω-conotoxin-GVIA peptide isolated from Conus geographus is a potent, selective, and irreversible inhibitor of N-type channels. Similarly, ω-conotoxin-MVIIA (called Prialt hereafter), a 25-amino acid peptide from the venom of Conus magnus is a potent blocker of N-type channels although acts in a reversible manner. Due to their peptidic nature, the cone snail toxins are not orally available and they must be delivered directly into the CNS via intrathecal administration.

N-type channels are highly concentrated in both dorsal root ganglia cell bodies and also in the synaptic terminals they make in dorsal horn of the spinal cord (laminae I and II).14,28 These primary afferents (mainly C-fibers and A-δ fibers) are implicated in the sensation of a variety of noxious painful stimuli including thermal, mechanical, and inflammatory. Critically, block of N-type currents inhibits the release of neuropeptides substance P and calcitonin gene-related peptide (CGRP) from sensory neurons.2931

Evidence suggests that the N-type channels targeted by intrathecal ω-conotoxin-GVIA and Prialt are not directly implicated in most acute thermal pain sensation (e.g., the hot plate and tail flick assays in rats) but rather play a more significant role in inflammatory and chronic neuropathic conditions.32 These include potent efficacy in both the early and late phase of the formalin model, antihyperalgesic and antiallodynic effects associated with the Chung and Bennett models, as well as antihyperalgesic actions in the capsaicin and carrageenan inflammatory models. There has been one report that Prialt alleviates the hyperalgesia and allodynia associated with a rat model of postoperative pain.33

In side-by-side comparisons in animal models of chronic inflammatory and neuropathic pain Prialt is at least 10 times more potent than intrathecally administered morphine. Interestingly, pretreatment with Prialt can also prevent the establishment of hyperalgesia and allodynia suggesting a possible role for N-type channels in the establishment of hypersensitive pain states. Although Prialt is opioid sparing, it does not bind opioid receptors or prevent the development morphine-induced tolerance.34

The N-type calcium channel target is also validated through the construction of mice strains in which the N-type gene has been genetically deleted.3537 Somewhat surprisingly given the generally wide CNS distribution of N-type channels and their demonstrated role in neurotransmission, other than a partial degree of lethality in one out of the three knockout strains reported, the N-type channel deficient mice display relatively few deleterious affects. Mating behavior and life span are normal and there are no reports of ataxias or other motor-related defects commonly associated with block of N-type channels by Prialt (see below). The only behavioral alteration that might be ascribed to CNS function were decreased anxiety-related behaviors associated with the elevated plus-maze, open-field, and acoustic startle tests in the homozygous N-type-deficient animals.37

All three N-type channel gene knockout strains exhibit abnormal responses to pain behaviors. Although not all labs examined the same animal models and there were some inconsistencies between labs regarding results for acute pain models (paw-flick, hot plate), the data clearly show that the N-type channel is required for the development of the hyperalgesia and allodynia associated with neuropathic pain, as well as for inflammatory pain.3538

In humans, Prialt has been examined in case studies (e.g., brachial plexus avulsion, spinal cord pain) as well as in open-label and double-blinded, placebo-controlled clinical trials for both nonmalignant (e.g., HIV-mediated neuropathic pain) and morphine-refractory malignant pain. Intrathecal Prialt provides statistically significant decreases in Visual Analog Scale of Pain Intensity scores across many of the chronic and severe conditions examined including in some instances providing complete pain relief in patients previously unresponsive to intrathecal morphine.3941 Interestingly, Prialt also appears to control the severe spasticity associated with spinal cord injury.42

The administration of Prialt is not without adverse effects in either animals or humans. Intrathecal administration in rats consistently shows serpentine tail movements and whole body shaking suggestive of cerebellar-related motor defects. In humans, intrathecal Prialt administration can result in severe but reversible psychiatric symptoms and neurological impairment including cognitive impairment, hallucinations, and changes in mood and consciousness.3941 Systemic administration of Prialt results in severe orthostatic hypotension, presumably from interactions with N-type channels in the sympathetic nervous system.43

Interestingly, even though both direct N-type channel blockade and spinal opioid receptor activation likely exert their antinociceptive effects at least in part via a common inhibition of neurotransmitter release, none of the N-type adverse effects appear similar to those commonly associated with opioid administration.44 Neither animals nor humans administered intrathecal Prialt show significant respiratory depression, constipation, sedation, loss of motor coordination, or the euphoria/stupor associated with opioids. Additionally, continuous spinal perfusion of Prialt over long periods of time appears to alleviate pain symptoms without either the requirement for increasing drug dosage over time (tolerance) or being accompanied by withdrawal symptoms upon abrupt termination of drug (addiction).3942 Conversely, morphine administration does not result in the observed ataxias associated with N-type channel blockade by Prialt.

That morphine works well in animal models examining acute nociception but that Prialt is only moderately effective suggests that both mechanistic and spatial mechanisms come into play. As noted, spinally administered opioids likely act by both activating potassium channels and also inhibiting presynaptic N-type channels, whereas Prialt only exerts its analgesic effects through inhibiting N-type channels. Additionally, it is highly likely that not all opioid receptors are specifically colocalized with presynaptic N-type channels and similarly that not all N-type channels are susceptible to opioid-dependent modulation.45 Indeed, centrally opioids are known to modulate multiple subtypes of widely distributed high-threshold calcium currents (including P/Q-type)16 and thus the potential for a wider range of opioid-related adverse effects is greater than that for the more restricted N-type calcium channel target.


The dorsal horn of the spinal cord is a critical integration site involved in processing signals resulting from a variety of noxious stimuli including thermal, mechanical, and inflammatory. The thinly myelinated A-δ and unmyelinated C fibers make their terminals onto interneurons in the superficial laminae I and II and both P/Q-type and N-type calcium channels are localized in the dorsal horn, suggesting that both channel subtypes contribute to afferent signaling. Interestingly, most individual terminals in the dorsal horn express N-type or P/Q-type channels but not both subtypes, suggesting that these channels are individually associated with distinct aspects of primary afferent signaling.46 Block of P/Q-type by intrathecal application of ω-agatoxin-IVA has only a mild affect on the allodynia associated with spinal nerve ligation, whereas blockade of N-type channels with Prialt has a major antinociceptive effect. Colocalization studies show that terminals expressing P/Q-type channels largely do not contain substance P, whereas those terminals using N-type channels to trigger release contain substance P.46 Taken together with data showing that ω-conotoxin GVIA inhibits the release of substance P, it appears that blockade of N-type channels in laminae I and II affects nociception particularly associated with substance P release (and likely also CGRP and glutamate that tend to colocalize with substance P containing terminals.47

It should be noted parenthetically that, as N-type channels are localized on both excitatory and inhibitory terminals in the spinal cord (including some interneurons), their inhibition could have quite variable physiological consequences dependent upon the nature of the specific signaling pathways affected. Also, it remains unknown whether there are distinct subtypes of spinal N-type channels with unique biophysical properties that might be differentially affected by drugs acting via state-dependent mechanisms.


In addition their direct role in transmitting nociceptive stimuli into the CNS via primary afferent terminals in the dorsal horn of the spinal cord, N-type channels may also play a key role in the hypersensitivity associated with certain neuropathic pain conditions. For example, both P/Q-type and N-type channels in the rostral ventromedial medulla contribute to tactile allodynia through activation of descending facilitatory systems.48,49


Although Prialt has been shown to offer significant therapeutic benefit in a number of chronic, opioid-unresponsive conditions, a case can be made that the development of future N-type channel therapeutics should address several issues.

1) The therapeutic index (ratio of relative toxicity to relative efficacy) of intrathecally administered Prialt is quite narrow in both animals (ratios range from 1.5–2.1) and in humans.3941 Clinically, Prialt must be titrated slowly in each individual patient, and typically doses are reached whereby some adverse affects are observed even before the dose is fully efficacious. Initial data with other natural peptides (e.g., ω-conotoxin-CVID and huwentoxin-I; see below) suggest that it may be possible to maintain the potent antinociceptive effects associated with N-type channel blockade and have fewer, less severe adverse effects.

2) The requirement that Prialt (or other peptide N-type channel blockers) be administered intrathecally is extremely limiting. Identifying safe and efficacious orally available N-type channel blockers is relatively straightforward to rationalize from both the patient and marketing perspectives. The invasive surgery and high costs associated with implantable pumps clearly limits the numbers of patients both eligible and willing to use Prialt regardless of its potential as a potent antinociceptive.

3) Voltage-gated ion channels are well known to exist in a number of discrete biophysical states (e.g., open, closed/resting, and inactivated) that presumably reflect distinct time-dependent and voltage-dependent conformations.50 It has also been well established that the interaction of various drugs (both antagonists and agonists) with voltage-gated ion channels are significantly different depending upon the particular channel state. Certain drugs preferentially interact with channel sites in specific conformations and in some instances drug-channel binding affinity can vary by orders of magnitude from state to state of the channel. This phenomenon is of particular relevance as it relates to both the physiological consequences of drug action but is equally important to the safety profile of most drugs interacting with ion channels.

The biophysical states of calcium channels, and hence drug interaction, can be affected by various parameters including both resting membrane potential and the frequency of stimulation. In the case of the widely clinically used L-type channel antagonists, Bean provided the first evidence that the 1,4-dihydropyridine L-type channel blockers likely provide an excellent therapeutic window due to their preferential binding and block of inactivated channels.51

In the case of N-type channels, an initial report found Prialt block to be reversed by strong membrane depolarization suggesting a state-dependent mechanism.52 However, in a thorough analysis under more relevant physiological conditions, Prialt block was found to occur in all states—the resting, open and inactivated conformations—and there was little evidence of frequency or voltage dependence.53 In this regard, the development of state-dependent N-type channel blockers would be predicted to significantly improve the therapeutic index over that for Prialt.

In consideration of blocking N-type channels for therapeutic intervention, there are some things that we either quite yet don't fully understand or have sufficient information to make definitive conclusions. For example, in the mammalian CNS, whereas N-type channels appear to be widely distributed (as evidenced by mRNA, immunohistochemical, and ω-conotoxin-GVIA binding studies), there seem to be relatively few adverse physiological consequences in knockout mice that completely lack all N-type channel activity. Similarly, there is good evidence for N-type channel expression in certain spinal motor neurons and neuroendocrine cells, and yet there is sparse evidence to indicate that animals lacking this channel suffer adverse neuroendocrine or motor affects. While it is possible that compensation by other calcium channel types overcomes any deleterious effects in the knockout animals, studies examining calcium current levels in the knockout mice do not find evidence for compensatory mechanisms.

Concerning a major direct involvement in motor transmission, whereas N-type channels have been described in spinal motor neurons and at mammalian neuromuscular junctions, they appear to account for a very small portion of neuromuscular terminals (<5%) compared with that for P/Q-type channels (~95%).46 Even then, N-type channels are only found at a subset of specific neuromuscular terminals (e.g., tibialis anterior, gastrocnemius, and soleus muscles) and appear not to be localized at presynaptic junctions associated with other muscle such as the diaphragm.

Given the relative lack of CNS-related physiological consequences reported in N-type gene knockout mice (which essentially mimics complete blockade of all N-type channels), what then causes the significant cardiovascular and CNS adverse effects found in animals and humans treated with the clinical N-type channel blocker Prialt? This issue remains to be adequately addressed and whether Prialt adverse affects are specifically related to the N-type target itself, the biophysical mechanism of action of Prialt block on N-type channels, or to some as yet to-be-described nonspecific effects of Prialt on other targets remains to be fully elucidated.

Interestingly, other natural peptides with high affinity and selectivity for the N-type channel do not appear to have similar deleterious effects in vivo. For example, AM336 (ω-conotoxin-CVID), a 27-amino acid peptide from Conus catus, has been shown to be a potent blocker of N-type currents and to displace radiolabeled ω-conotoxin-GVIA binding at potencies similar to that for both ω-conotoxin-GVIA and ω-conotoxin-MVIIA.54 In animal models of persistent inflammatory and neuropathic pain, AM336 results in potent dose-dependent antinociception. However, despite AM336's similar high potency block of N-type channels compared to that for ω-conotoxins-GVIA and -MVIIA, it appears to possess a remarkably better CNS safety profile in animals.55,56 In rodents, intrathecally administered AM336 produces a five-fold better therapeutic index (ratio of relative toxicity to relative potency) concerning the incidence of the serpentine tail movements and whole body shaking observed for similarly administered Prialt.

In another example, intrathecal administration of huwentoxin-I, a 33-amino acid peptide from the venom of the Chinese bird spider Ornithoctonus huwena appears as effective as ω-conotoxin-MVIIA in both the early and late phases of the formalin model of inflammatory pain.57 However, whereas huwentoxin-I blocks N-type channels with high affinity (EC50 = 100 nm) and selectivity, at high doses in vivo it exhibits a significantly lower degree of the motor dysfunction and ataxia compared with that for Prialt.

It is tempting to speculate that the significantly better therapeutic window in animals of AM336 compared with that for Prialt is due to the fact that, in radioligand binding assays, AM336 is approximately 100-fold more selective for N-type channels over P/Q-type channels compared to Prialt. P/Q-type channels are the major calcium channel subtypes implicated in triggering neurotransmission in the CNS in mammals, and even a moderate degree of blockade by intrathecally administered Prialt would be predicted have significant deleterious effects on central and motor neuron functions. It is also tempting to speculate that the fact that the N-type channel gene knockout mice do not exhibit the cerebellar ataxia or whole body shaking characteristic of Prialt administration reflects its action on central targets other than the N-type calcium channel.

N-type currents (along with other calcium channels subtypes) are described in both peripheral sensory neurons and neuroendocrine cells, and it remains unclear as to the specific consequences of N-type channel blockade on peripheral transmission and endocrine function. The ability to predict potential deleterious affects concerning N-type channel blockade in sympathetic neurons is far from clear. In some sympathetic neurons, neurotransmitter release mediate by N-type channels appears to be frequency dependent although not necessarily in the expected manner. In both carotid body and postganglionic sympathetic nerve terminals, for example, release triggered through N-type channel activation is actually higher at lower stimulation frequencies (0.4–2 Hz) than at higher frequencies (30 Hz).58 In other sympathetic neurons (e.g., noradrenergic constrictions of the inferior vena cava and uterine artery), there is no affect of stimulation frequency on N-type channel-dependent release, whereas in still other cells sympathetic-mediated vasoconstriction does not appear to involve N-type channel-mediated release.59

In one homozygous N-type channel gene knockout strain, it was found that heart rate and blood pressure were unaffected by the complete lack of N-type channels, whereas in another independent strain both heart rate and blood pressure were elevated.35,37 Affects on the carotid baroreflex were more definitive in that N-type gene knockout mice appeared to lack the normal response to carotid artery occlusion. Additionally, a contribution to sympathetic neurotransmission was suggested in that N-type-deficient mice showed an impaired cardiac inotropic response, although contradictorily it was noted that circulating norepinephrine levels were actually normal.35

In support of the notion for developing state-dependent N-type blockers for peripheral administration, N-type currents in adrenal chromaffin cells exhibit variable inactivation characteristics with a large fraction of the channels being resistant to inactivation even during prolonged depolarization.6 Under such circumstances it could be envisioned that N-type blockers with significantly higher affinity for the inactivated states would have minimal affects on N-type channel-mediated endocrine functions.

Additional factors likely relevant to the discussion include the fact that it is well known that all neurotransmission is not created equal: different size synaptic vesicles exist, the different vesicles often contain distinct types of neurotransmitters and neuropeptides, and release can be differentially dependent upon the nature of stimulation (e.g., in some cases release from small vesicles can occur in response to single or low frequency stimuli, whereas large vesicle release can require stronger stimuli and/or higher frequency stimulation). Release dependent upon these various factors has been predicted to involve both differential vesicle interactions with SNARE proteins and also the involvement distinct subtypes of presynaptic calcium channels. Overall, the data suggest that some portion of sympathetic function would likely not be affected by N-type channel blockade, whereas in other instances state-dependent N-type channel blockers aimed at selectively targeting channel states associated with higher frequency stimulation might have minimal affect on normal sympathetic functions such as those associated with carotid bodies.


The selective N-type calcium channel peptide antagonist Prialt has demonstrated significant antinociceptive action even in morphine-unresponsive clinical situations. Whereas Prialt has a narrow therapeutic window, the general lack of serious opioid-related side effects such as respiratory depression, addiction, and tolerance has made the N-type channel an attractive therapeutic target for a variety of chronic/neuropathic pain conditions. Future directions include improving on both Prialt's limited delivery options and its safety profile through the development of small molecule, orally available N-type channel blockers that act via state-dependent mechanisms. Issues that remain to be fully elucidated include reconciliation of conflicting data between the relatively significant adverse effects observed for Prialt compared with the more mild effects observed by other peptidic N-type channel blockers and in N-type channel gene knockout mice. Additionally, the physiological consequences of systemically blocking N-type channels in the peripheral nervous system still needs to be adequately addressed.


I thank Dr. Gerald Zamponi for helpful comments. The author is a Professor in the Michael Smith Laboratories, University of British Columbia, and is also the founder and Chief Scientific Officer of Neuromed Technologies, Inc. Work in the Michael Smith Laboratories is supported by the Canadian Institutes for Health Research and by a Canadian Research Tier 1 Chair in Biotechnology and Genomics.


1. Snutch TP, Peloquin J, Mathews E, McRory J. Molecular properties of voltage-gated calcium channels. In: Voltage-gated calcium (Zamponi G, ed), pp 61–94. New York: Landes Bioscience, 2005.
2. Catterall WA. Biochemical studies of Ca2+ channels. In: Voltage-gated calcium (Zamponi G, ed), pp 48–60. New York: Landes Bioscience, 2005.
3. Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel α1 subunit. Neuron 9: 1099–1115, 1992. [PubMed]
4. Dunlap K, Luebke JI, Turner TJ. Exocytotic Ca2+ channels in mammalian central neurons. Trends Neurosci 18: 89–98, 1995. [PubMed]
5. Janis RJ, Triggle DJ. In: Calcium channels: their properties, functions, regulation and clinical relevance. London: CRC, 1991.
6. Cahill AL, Hurley JH, Fox AP. Coexpression of cloned α(1B), β(2a), and α(2)/δ subunits produces non-inactivating calcium currents similar to those found in bovine chromaffin cells. J Neurosci 20: 1685–1693, 2000. [PubMed]
7. Stea A, Soong TW, Snutch TP. Determinants of PKC-dependent modulation of a family of neuronal calcium channels. Neuron 15: 929–940, 1995. [PubMed]
8. Bourinet E, Soong TW, Stea A, Snutch TP. Determinants of the G-protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci USA 93: 1486–1491, 1996. [PMC free article] [PubMed]
9. Artalejo CR, Perlman RL, Fox AP. ω-Conotoxin GVIA blocks a Ca2+ current in bovine chromaffin cells that is not the “classic” N-type. Neuron 8: 85–95, 1992. [PubMed]
10. Dubel SJ, Starr TVB, Hell J, Ahlijanian MK, Enyeart JJ, Catterall WA, Snutch TP. Molecular cloning of the α-1 subunit of an ω-conotoxin-sensitive calcium channel. Proc Natl Acad Sci USA 89: 5058–5062, 1992. [PMC free article] [PubMed]
11. Lin Z, Haus S, Edgerton J, Lipscombe D. Identification of functionally distinct isoforms of the N-type Ca2+ channel in rat sympathetic ganglia and brain. Neuron 18: 153–166, 1997. [PubMed]
12. Lin Z, Lin T, Schorge S, Pan JQ, Beierlein M, Lipscombe D. Alternative splicing of a short cassette exon in α1B generates functionally distinct N-type calcium channels in central and peripheral neurons. J Neurosci 19: 5322–3531, 1999. [PubMed]
13. Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, Monteil A, Zamponi GW, Nargeot J, Snutch TP. Phenotypic variants of P- and Q-type calcium channels are generated by alternative splicing of the α1A subunit gene. Nat Neurosci 2: 407–415, 1999. [PubMed]
14. Kerr LM, Filloux F, Olivera BM, Jackson H, Wamsley JK. Autoradiographic localization of calcium channels with [125I] ω-conotoxin in rat brain. Eur J Pharmacol 146: 181–183, 1988. [PubMed]
15. Beedle AM, Zamponi GW. Modulation of high voltage-activated calcium channels by G protein coupled receptors. In: Calcium channel pharmacology (McDonough SI, ed), pp 331–367. New York: Kluwer Academic/Plenum Publishers, 2004.
16. Soldo BL, Moises HC. μ-Opioid receptor activation inhibits N- and P-type Ca2+ channel currents in magnocellular neurones of the rat supraoptic nucleus. J Physiol (Lond) 513: 787–804, 1998. [PMC free article] [PubMed]
17. Pan X, Ikeda SR, Lewis DL. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol Pharmacol 49: 707–714, 1996. [PubMed]
18. Sun L, Miller RJ. Multiple neuropeptides Y receptors regulate K+ and Ca2+ channels in acutely isolated neurons from the rat arcuate nucleus. J Neurophysiol 81: 1391–1403, 1999. [PubMed]
19. Shapiro MS, Hille B. Substance P and somatostatin inhibit calcium currents in rat sympathetic neurons via different G protein pathways. Neuron 10: 11–20, 1993. [PubMed]
20. Zamponi GW, Bourinet E, Nelson D, Nargeot J, Snutch TP. Crosstalk between G-proteins and protein kinase C mediated by the calcium channel α1 subunit. Nature 385: 442–446, 1997. [PubMed]
21. Zamponi GW, Snutch TP. Decay of prepulse facilitation during G-protein inhibition of N-type calcium channels involves binding of a single Gβγ subunit. Proc Natl Acad Sci USA 95: 4035–4039, 1998. [PMC free article] [PubMed]
22. Patil PG, de Leon M, Reed RR, Dubel SJ, Snutch TP, Yue DT. Elementary events underlying voltage-dependent G-protein inhibition of N-type calcium channels. Biophys J 71: 2509–2521, 1996. [PMC free article] [PubMed]
23. Sheng ZH, Rettig J, Takahashi M, Catterall WA. Identification of a syntaxin-binding site on N-type calcium channels. Neuron 13: 1303–1313, 1994. [PubMed]
24. Jarvis SE, Zamponi GW. Distinct molecular determinants govern syntaxin 1A-mediated inactivation and G-protein inhibition of N-type calcium channels. J Neurosci 21: 2939–2948, 2001. [PubMed]
25. Jarvis SE, Barr W, Feng Z-P, Hamid J, Zamponi GW. Molecular determinants of syntaxin 1 modulation of N-type calcium channels. J Biol Chem 277: 44399–44407, 2002. [PubMed]
26. Cruz LJ, Olivera BM. Calcium channel antagonists. ω-Conotoxin defines a new high affinity site. J Biol Chem 261: 6230–6233, 1986. [PubMed]
27. Olivera BM, Cruz LJ, de Santos V, LeCheminant GW, Griffin D, Zeikus R, McIntosh JM, Galyean R, Varga J, Gray WR. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using ω-conotoxin from Conus magus venom. Biochemistry 26: 2086–2090, 1987. [PubMed]
28. Gohil K, Bell JR, Ramachandran J, Miljanich GP. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium channel antagonist, SNX-230 (ω-conopeptide MVIIC). Brain Res 653: 258–266, 1994. [PubMed]
29. Maggi CA, Giuliani S, Santicioli P, Tramontana M, Meli A. Effects of ω conotoxin on reflex responses mediated by activation of capsaicin-sensitive nerves of the rat urinary bladder and peptide release from rat spinal cord. Neurosci 34: 243–250, 1990. [PubMed]
30. Santicioli P, Del Biaanco E, Tramontana M, Geppetti P, Maggi CA. Release of calcitonin gene-related peptide-like immunoreactivity induced by electrical field stimulation from rat spinal afferents is mediated by conotoxin sensitive calcium channels. Neurosci Lett 136: 161–164, 1992. [PubMed]
31. Evans AR, Nicol GD, Vasko MR. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res 712: 265–273, 1996. [PubMed]
32. Vanegas H, Schaible H-G. Effects of antagonists to high-threshold Ca channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 85: 9–18, 2000. [PubMed]
33. WangY-X, Pettus M, Gao D, Phillips C, Bowersox SS. Effects of intrathecal administration of ziconotide, a selective neuronal N-type Ca channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 84: 151–158, 2000. [PubMed]
34. Wang Y-X, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive Ca channels, with morphine on nociception in rats. Pain 84: 271–281, 2000. [PubMed]
35. Ino M, Yoshinaga T, Wakamori M, Miyamoto N, Takahashi E, Sonoda J, Kagaya T, Oki T, Nagasu T, Nishizawa Y, Tanaka I, Imoto K, Aizawa S, Koch S, Schwartz A, Niidome T, Sawada K, Mori Y. Functional disorders of the sympathetic nervous system in mice lacking the α 1B subunit (Cav 2.2) of N-type calcium channels. Proc Natl Acad Sci USA 98: 5323–5328, 2001. [PMC free article] [PubMed]
36. Kim C, Jun K, Lee T, Kim S-S, McEnery MW, Chin H, Kim H-L, Park JM, Kim DW, Jung SJ, Kim J, Shin H-S. Altered nociceptive response in mice deficient in the α1B subunit of the voltage-dependent Ca channel. Mol Cell Neurosci 18: 235–245, 2001. [PubMed]
37. Saegusa H, Kurihara T, Zong S, Kazuno A, Matsuda Y, Nonaka T, Han W, Toriyama H, Tanabe T. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca channel. EMBO J 20: 2349–2356, 2001. [PMC free article] [PubMed]
38. Saegusa H, Matsuda Y, Tanabe T. Effects of ablation of N- and R-type Ca(2+) channels on pain transmission. Neurosci Res 43: 1–7, 2002. [PubMed]
39. Brose WG, Gutlove DP, Luther RR, Bowersox SS, McGuire D. Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 13: 256–259, 1997. [PubMed]
40. Mathur VS. Ziconotide: a new pharmacological class of drug for the management of pain. Semin Anesthesia Perioperative Med Pain 19: 67–75, 2000.
41. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce D, Mangieri EA, Luther RR, Mayo M, McGuire D, Ellis D. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291: 63–70, 2004. [PubMed]
42. Ridgeway B, Wallace M, Gerayli A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain 85: 287–289, 2000. [PubMed]
43. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol 30: 400–403, 1997. [PubMed]
44. Malmberg AB, Yaksh TL. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception. J Neurosci 14: 4882–4890, 1994. [PubMed]
45. Schroeder JE, McCleskey EW. Inhibition of Ca2+ currents by a μ-opiod in a defined subset of rat sensory neurons. J Neurosci 13: 867–873, 1993. [PubMed]
46. Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci 18: 6319–6330, 1998. [PubMed]
47. Murakami M, Nakagawasai O, Suzuki T, Mobarakeh II, Sakurada Y, Murata A, Yamadera F, Miyoshi I, Yanai K, Tan-No K, Sasano H, Tadano T, Iijima T. Antinociceptive effect of different types of Ca channel inhibitors and the distribution of various Ca channel α1 subunits in the dorsal horn of spinal cord in mice. Brain Res 1024: 122–129, 2004. [PubMed]
48. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 25: 319–325, 2002. [PubMed]
49. Urban MO, Ren K, Sablad M, Park KT. Medullary N-type and P/Q-type Ca channels contribute to neuropathy-induced allodynia. Neuroreport 16: 563–566, 2005. [PubMed]
50. Hille B. Ionic channels of excitable membranes. Sunderland, MA: Sinauer Associates, 2001.
51. Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci USA 81: 6388–6392, 1984. [PMC free article] [PubMed]
52. Stocker JW, Nadasdi L, Aldrich RW, Tsien RW. Preferential interaction of ω-conotoxins with inactivated N-type Ca2+ channels. J Neurosci 17: 3002–3013, 1997. [PubMed]
53. Feng Z-P, Doering CJ, Winkfein RJ, Beedle AM, Spafford JD, Zamponi GW. Determinants of inhibition of transiently expressed voltage-gated calcium channels by ω-conotoxins GVIA and MVIIA. J Biol Chem 278: 20171–20178, 2003. [PubMed]
54. Lewis RJ, Nielsen KJ, Craik DJ, Loughnan ML, Adams DA, Sharpe IA, Luchian T, Adams DJ, Bond T, Thomas L, Jones A, Matheson JL, Drinkwater R, Andrews PR, Alewood PF. Novel ω-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 275: 35335–35344, 2000. [PubMed]
55. Scott DA, Wright CE, Angus JA. Actions of intrathecal ω-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 451: 279–286, 2002. [PubMed]
56. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 96: 119–127, 2002. [PubMed]
57. Chen J-Q, Zhang Y-Q, Dai J, Luo Z-M, Liang S-P. Antinociceptive effects of intrathecally administered huwentoxin-I, a selective N-type Ca channel blocker, in the formalin test in conscious rats. Toxicon 45: 15–20, 2005. [PubMed]
58. Uhrenholt TR, Nedergaard OV. Involvement of different calcium channels in the depolarization-evoked release of noradrenaline from sympathetic neurones in rabbit carotid artery. Basic Clin Pharm Tox 97: 109–114, 2005. [PubMed]
59. Morris, JL, Ozols DI, Lewis RJ, Gibbins IL, Jobling P. Differential involvement of N-type Ca channels in transmitter release from vasoconstrictor and vasodilator neurons. Br J Pharmacol 141: 961–970, 2004. [PMC free article] [PubMed]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...